Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Effects of Treating Obstructive Sleep Apnea in Epilepsy
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Status: Enrolling
Updated:  7/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Status: Enrolling
Updated: 7/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Status: Enrolling
Updated:  7/20/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Status: Enrolling
Updated: 7/20/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Status: Enrolling
Updated:  7/20/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Status: Enrolling
Updated: 7/20/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Status: Enrolling
Updated:  7/20/2016
Vanderbilt University
mi
from
Nashville, TN
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Effects of Treating Obstructive Sleep Apnea in Epilepsy
Status: Enrolling
Updated: 7/20/2016
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
Pharmacokinetic Evaluation of Nontuberculous Mycobacterial Antibiotics in Cystic Fibrosis Versus Controls
Status: Enrolling
Updated:  7/25/2016
Children's Hospital Colroado
mi
from
Aurora, CO
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
Pharmacokinetic Evaluation of Nontuberculous Mycobacterial Antibiotics in Cystic Fibrosis Versus Controls
Status: Enrolling
Updated: 7/25/2016
Children's Hospital Colroado
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
University of Alabama
mi
from
Birmingham, AL
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Banner University of Arizona Medical Center
mi
from
Tucson, AZ
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Banner University of Arizona Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Stanford University
mi
from
Palo Alto, CA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
UC Davis Medical Center
mi
from
Sacramento, CA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
National Jewish Health
mi
from
Denver, CO
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Yale University
mi
from
New Haven, CT
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Tampa General Hospital
mi
from
Tampa, FL
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
St. Luke's CF Center of Idaho
mi
from
Boise, ID
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
St. Luke's CF Center of Idaho
mi
from
Boise, ID
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Northwestern University
mi
from
Chicago, IL
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Saint Francis Medical Center
mi
from
Peoria, IL
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Indiana University
mi
from
Indianapolis, IN
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Via Christi Research
mi
from
Wichita, KA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Via Christi Research
mi
from
Wichita, KA
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
University of Kentucky
mi
from
Lexington, KY
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Maine Medical Center
mi
from
Portland, ME
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Maine Medical Center
mi
from
Portland, ME
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Boston Children's Hospital
mi
from
Boston, MA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Univ of Massachusetts Med School
mi
from
Worcester, MA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Wayne State University-Harper
mi
from
Detroit, MI
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Wayne State University-Harper
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Spectrum Health Butterworth Hospital
mi
from
Grand Rapids, MI
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Spectrum Health Butterworth Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
St. Louis University
mi
from
St. Louis, MO
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
St. Louis University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Washington University
mi
from
St. Louis, MO
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Morristown Medical Center
mi
from
Morristown, NJ
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Columbia University
mi
from
New York, NY
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Rainbow Babies and Children's Hospital - Case Medical Center
mi
from
Cleveland, OH
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Rainbow Babies and Children's Hospital - Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Nationwide Children's Hospital
mi
from
Columbus, OH
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
ProMedica Toledo Children's Hospital
mi
from
Toledo, OH
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
ProMedica Toledo Children's Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Oregon Health and Science University
mi
from
Portland, OR
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Medical University of South Carolina
mi
from
Charleston, SC
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Dell Children's Hospital | Austin Children's Chest Associates
mi
from
Austin, TX
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Dell Children's Hospital | Austin Children's Chest Associates
mi
from
Austin, TX
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Texas Children's Hospital
mi
from
Houston, TX
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
University of Utah
mi
from
Salt Lake City, UT
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated:  7/27/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status: Enrolling
Updated: 7/27/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials